

Please type a plus sign (+) before this box → +

PTO/SB/08B (10-96)  
 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			MAY 15 2002		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number		09/808,718	
			Filing Date		3/15/2001	
			First Named Inventor		Johnson <i>et al.</i>	
			Group Art Unit		<del>1653</del> 1644	
			Examiner Name		Unknown	
Attorney Docket Number		UF-10164R				
Sheet	1	of	2			

RECEIVED  
 MAY 20 2002  
 TECH CENTER 1600/2910

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
OIP MAY 15 2002 PATENT & TRADEMARK OFFICE		JOHNSON, H.M., <i>et al.</i> "Superantigens: Structure and relevance to human disease" <i>Proc. Soc. Exp. Biol. Med.</i> (1996) 212: 99-109.	
		MOLLICK, J.A. <i>et al.</i> "Class II MHC molecules are specific receptors for staphylococcal enterotoxin" <i>A. Science</i> (1989) 244: 817-820.	
		D'ORAZIO, J.A. and Stein-Streilein "Human natural killer (NK) cells present staphylococcal enterotoxin B (SEB) to T lymphocytes" <i>Clin. Exp. Immunol.</i> (1996) 104: 366-373.	
		RUSSEL, J.K. <i>et al.</i> "The I-A $\beta$ b region (65-85) is a binding site for the superantigen staphylococcal enterotoxin" <i>A. Biochem. Biophys. Res. Comm.</i> (1990) 168: 696-701.	
		RUSSEL, J.K. <i>et al.</i> "Both helices along the major histocompatibility complex binding cleft are required for staphylococcal enterotoxin A function" <i>Proc. Natl. Acad. Sci. USA</i> (1991) 88: 7228-7232.	
		CALLAHAN, J.E., <i>et al.</i> "Stimulation of B110.BR T cells with superantigenic staphylococcal enterotoxins" <i>J. Immunol.</i> (1990) 144: 2473-2479.	
		MARRACK, P. and J. Kappler "The Staphylococcal enterotoxins and their relatives" <i>Science</i> (1990) 248: 705-711.	
		PEAVY, D.L., <i>et al.</i> "Mitogenic effects of endotoxin and SEB on mouse spleen cells and human lymphocytes" <i>J. Immunol.</i> (1970) 105: 1453-1458.	
		LANGFORD, M.P., <i>et al.</i> "Biological effects of staphylococcal enterotoxin A on human peripheral lymphocytes" <i>Infect. Immun.</i> (1978) 22: 62-68.	
		CARLSSON, R and H.O. Sjogren "Kinetics of IL-2 and IFN $\gamma$ production, expression of IL-2 receptors, and cell proliferation in human mononuclear cells exposed to SEA." <i>Cell. Immunol.</i> (1985) 96: 175-183.	
	JOHNSON, H.M. and H.I. Magazine "Potent mitogenic activity of staphylococcal enterotoxin A requires induction of interleukin 2" <i>Int. Arch. Allergy Appl. Immunol.</i> (1988) 87: 87-90.		

Examiner Signature	<i>Ewaldt</i>	Date Considered	5/6/03
--------------------	---------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside the box → +

Approved for use through 10/31/99. PTO/STP 08B (10-96)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	09/808,718
				Filing Date	3/15/2001
				First Named Inventor	Johnson <i>et al.</i>
				Group Art Unit	1653 1644
				Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket Number	UF-10164R

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>JS</i>		KAWABE, Y. and A. Ochi "Selective anergy of V beta 8+, CD4+ T cells in staphylococcus enterotoxin B-primed mice" <i>J. Exp. Med.</i> (1990) 172: 1065-1070.	
		KOTZIN, B.L. <i>et al.</i> "Superantigens and their potential role in human disease" <i>Adv. Immunol.</i> (1993) 54: 99-166.	
		MUJTABA, M.G., <i>et al.</i> "IFN-tau supresses both the autoreactive humeral and cellular immune responses and induces stable remission in mice with chronic experimental allergic encephalomyelitis" <i>Cell. Immunol.</i> (1998) 186: 94-102.	
		TZU, W. and W.R. Fleishmann "Efficacy of B16 melanoma cells exposed in vitro to long-term IFN treatment (B16 cells) as a tumor vaccine in mice" <i>J. Interferon Cytokine Res.</i> (1998) 18: 829-839.	
		HOBEIKA, A.C., <i>et al.</i> "IFN $\gamma$ induction of p21 <sup>WAF1</sup> in prostate cancer cells: role in cell cycle, alteration of phenotype and invassive potential" <i>Int. J. Cancer</i> (1998) 77: 138-145.	
		KOMINSKY, S.L., <i>et al.</i> "IFN $\gamma$ inhibition of cell growth in glioblastomas correlates with increased levels of p21 <sup>WAF1/CIP1</sup> ," <i>Oncogene</i> (1998) 17: 2973-2979.	
<i>JS</i>		HOBEIKA, A.C., <i>et al.</i> "IFN $\gamma$ induction of p21 <sup>WAF1</sup> is required for cell cycle inhibition and suppression of apoptosis" <i>J. Interferon Cytokine Res.</i> (1999) 19: 1351-1361.	

Examiner Signature	<i>Eusebio</i>	Date Considered	5/6/03
--------------------	----------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

RECEIVED

MAY 20 2002

PTO CENTER 1600/2900

Please type a plus sign (+) inside this box ☐ +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number 09/808,718

Filing Date 3/15/2001

First Named Inventor Johnson et al.

Group Art Unit 1653-1644

Examiner Name Unknown

Attorney Docket Number UF-10164R

RECEIVED

MAR 01 2001

TECH CENTER

1600/2900

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
A/C		5,545,716		Johnson et al.	08-13-1996	
		5,859,207		Johnson, et al.	01-12-1999	
		5,519,114		Johnson, et al.	05-21-1996	
		5,795,974		Cole, et al.	08-18-1998	
		5,968,514		Johnson, et al.	10-19-1999	
		5,891,438		Silverman	04-06-1999	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
A/C			WO 98/26747		06-25-1998		
			WO 91/10680		07-25-1991		

Examiner  
Signature

Ewaldt

Date

Considered

5/6/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside the box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	09/808,718
Filing Date	3/15/2001
First Named Inventor	Johnson et al.
Group Art Unit	1653-1644
Examiner Name	Unknown
Attorney Docket Number	UF-10164R

RECEIVED  
MAR 06 2002  
TECH CENTER 1600/2900

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>[Signature]</i>		KOMINSKY, S.L. et al. "Vaccination with irradiated tumor cells followed by superantigen administration elicits a potent and protective anti-tumor immune response in C57BL/6 mice." <i>Proceedings of the 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco.</i> (April 1-5, 2000) 41: 114.	
<i>[Signature]</i>		TORRES, B.A. et al. "Superantigens induce potent and protective immune responses to weak melanoma-specific antigens." <i>FASEB Journal for Experimental Biology.</i> (2001) 15(5): a1201.	
<i>[Signature]</i>		APFFEL, Charles A., et al. "Tumor Rejection in Experimental Animals Treated with Radioprotective Thiols" <i>Cancer Research.</i> (1975) 35: 429-437.	

Examiner Signature	<i>[Signature]</i>	Date Considered	5/6/03
--------------------	--------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231